We are Dedicated to
Biopharmaceutical
Research & Advancement

What We Do
Generex Biotechnology Corp., is a biopharmaceutical company that is actively involved in discovery, research, development, and financing of new compounds, therapies, diagnostics, delivery systems, and medical technologies.
News
  1. Generex Announces Reverse Stock Split
    March 14, 2017
    MIRAMAR, Florida & TORONTO, Canada, March 14, 2017 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCPink:GNBT) today announced a reverse stock split of its shares of common stock at a ratio of 1-for-1000. As of the open of the market on March 14, 2017, the Company’s common stock will begin trading on a split-adjusted basis.
    READ MORE
  2. Generex Announces Elimination of Outstanding Derivative Securities
    February 15,2017
    MIRAMAR, Florida & TORONTO, Canada, February 15, 2017 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCPink:GNBT) today announced that it has achieved the elimination of its outstanding derivative securities.
    READ MORE
  3. Generex Provides Update on Deal to Acquire Controlling Equity Interest in Emmaus Life Sciences, Inc.
    February 9, 2017
    MIRAMAR, Florida & TORONTO, Canada, February 9, 2017 (BUSINESS WIRE) – On January 23, 2017 Generex Biotechnology Corporation (OTCPink:GNBT) announced a letter of intent for the acquisition of a controlling equity interest in Emmaus Life Sciences, Inc. (www.emmauslifesciences.com) (“Emmaus”). The Company filed a Form 8-K Current Report in respect of the transaction with the U.S. Securities and Exchange Commission (SEC) (www.sec.gov) on January 20, 2017. That 8-K provides comprehensive and detailed descriptions of the transaction terms. Generex today announced that Emmaus has granted to Generex an extension of the payment date for an interim cash consideration payment in the amount of $1,500,000 to February 16, 2017.
    READ MORE
  4. Generex Provides Access Information for Investor Conference Call Scheduled for February 22, 2017
    February 21, 2017
    MIRAMAR, Florida, February 21, 2017 (BUSINESS WIRE) -- Generex Biotechnology Corporation (OTCPink:GNBT) today announced the following access information for its investor conference call, to be hosted by Joseph Moscato, Company President & Chief Executive Officer, and his management team, tomorrow, Wednesday, February 22, 2017, at 10 am. Eastern time:
    READ MORE